Bayan Health review

Six prices describe different treatments

Bayan Health lists standard compounded semaglutide at $129 per month and tirzepatide at $149, with microdose tiers at $99 and $119. Needle-free oral drops are also listed at $99 and $119. The products are priced openly without an account, making the menu easy to inspect. The smaller figures belong to different treatment categories, however, rather than establishing that a standard injection can be purchased at the microdose price. Ask the clinician which actual preparation and quantity are appropriate before comparing cost.

The injection descriptions use a once-weekly schedule and include vitamin B6. That additive does not establish improved weight loss or fewer side effects. Nor does a microdose label establish universal suitability, greater safety, or results equivalent to another prescription. Request the complete formulation and written directions for the proposed treatment. A monthly subscription describes payment; it does not determine a clinical progression or tell a patient to adjust the amount independently to match the cheapest tier.

Coming soon does not mean approved or available

The catalog advertises retatrutide as coming soon under the label GLP-3. Retatrutide remains investigational rather than an FDA-approved medicine, and GLP-3 is a marketing nickname rather than a formal medication class. A future-product tile is not evidence of a licensed finished product, an approved indication, or clinical suitability. Its presence deserves attention when assessing the service's product claims, without treating the tile as proof that a patient has already been supplied the drug.

Other coming-soon tiles include orforglipron and oral tablets for the two tracked molecules. They have no published prices and should not inherit a nearby $99 amount. Each card needs its own availability, formulation, and financial explanation. In particular, a drug's presence elsewhere as an approved branded product would not automatically validate a different compounded offer or establish that a future Bayan product is that brand. Ask what the service would actually prescribe and dispense now.

Oral drops need their own evidence discussion

The site does not publish pharmacokinetic evidence supporting its particular oral-drop route. That limitation should prompt a product-specific discussion rather than an assumption that the drops perform like an injection or an approved oral medicine. Milligrams taken by one route should not be used to calculate an independent switch to another. The clinician needs to explain the proposed preparation and instructions, and the pharmacy needs to supply clear concentration, storage, quantity, and labeling information.

Bayan does not publicly name a dispensing pharmacy or provide a complete state list. Confirm both before submitting a detailed health history or paying. The company describes licensed-clinician guidance, but that general statement does not identify who would assess you or answer continuing questions. Ask for the medical practice, assigned professional, and pharmacy contact. Compounded semaglutide and tirzepatide are not FDA approved, regardless of whether their ingredients also appear in familiar branded medicines.

A simple storefront still needs a clear agreement

Each product is sold as a monthly subscription. Ask when another charge occurs, how to cancel, and what happens once medication is prepared. A visible price is useful transparency without establishing refund rights, included follow-up, or the cost of an additional appointment. Keep the actual supply and renewal schedule attached to the order rather than assuming every subscription labeled monthly includes the same number of weeks or the same clinical contact as another service.

Bayan may interest someone who wants to see several formulation and dose categories before applying, but the unnamed care partners and investigational-product advertising warrant direct answers. The public material does not substantially address pregnancy, breastfeeding, postpartum timing, or PCOS. Discuss relevant needs with the clinician and existing care team. Choose on an identifiable current prescription, full agreement, and accessible follow-up, keeping standard injections, microdoses, oral drops, and unpriced future products separate throughout the comparison.